XORTX Therapeutics Inc
XRTX0.747USD
+0.022+3.00%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.83MValor de mercado
PerdaP/L TTM
Mais detalhes de XORTX Therapeutics Inc Empresa
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
Informações da empresa
Código da empresaXRTX
Nome da EmpresaXORTX Therapeutics Inc
Data de listagemSep 30, 2015
CEODr. Allen W. Davidoff, Ph.D.
Número de funcionários2
Tipo de títulosOrdinary Share
Fim do ano fiscalSep 30
Endereço3710 - 33rd Street NW
CidadeCALGARY
Bolsa de valoresTSX Venture Exchange (former Canadian Ventures Exchange)
PaísCanada
Código postalT2L 2M1
Telefone14034557727
Sitehttps://www.xortx.com/
Código da empresaXRTX
Data de listagemSep 30, 2015
CEODr. Allen W. Davidoff, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James (Jim) Fairbairn
Mr. James (Jim) Fairbairn
Chief Financial Officer
Chief Financial Officer
6.95K
+314.44%
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James (Jim) Fairbairn
Mr. James (Jim) Fairbairn
Chief Financial Officer
Chief Financial Officer
6.95K
+314.44%
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 15 de jul
Atualizado em: ter, 15 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Davidoff, Allen Warren
3.18%
Giovinazzo (Anthony)
0.25%
Van Damme (Paul Joseph)
0.19%
Other
96.38%
Investidores
Investidores
Proporção
Davidoff, Allen Warren
3.18%
Giovinazzo (Anthony)
0.25%
Van Damme (Paul Joseph)
0.19%
Other
96.38%
Tipos de investidores
Investidores
Proporção
Individual Investor
3.41%
Other
96.59%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
17
129.44K
3.42%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
2023Q3
20
176.53K
8.83%
-185.14K
2023Q2
19
179.60K
8.98%
-178.94K
2023Q1
18
180.91K
11.39%
-170.46K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Davidoff, Allen Warren
112.26K
2.96%
+800.00
+0.72%
Jun 23, 2025
Giovinazzo (Anthony)
9.63K
0.25%
--
--
Apr 30, 2025
Van Damme (Paul Joseph)
7.11K
0.19%
--
--
Apr 30, 2025
Clearstead Advisors LLC
277.00
0.01%
--
--
Mar 31, 2025
National Bank of Canada
174.00
0%
-1.44K
-89.21%
Mar 31, 2025
Armistice Capital LLC
--
0%
-265.00K
-100.00%
Mar 31, 2025
UBS Financial Services, Inc.
--
0%
-17.43K
-100.00%
Mar 31, 2025
RBC Dominion Securities, Inc.
--
0%
-1.49K
-100.00%
Mar 31, 2025
Osaic Holdings, Inc.
--
0%
-1.15K
-100.00%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Data
Tipo
Proporção
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
Oct 12, 2023
Merger
9<1
